Doug Hampton

Postbiotics, Connected Diet Care, Digital OTC Therapy and AI-powered Precision Skin, Hair, and Oral Care

by

DUBLIN, June 9, 2023 /PRNewswire/ — The “Self-Care: Enabling Technologies and Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Self-Care: Enabling Technologies and Growth Opportunities comprises an analysis of physical self-care technologies and growth opportunities. It also provides actionable insights into the patent landscape across each physical self-care segment. Self-care is a proactive and customized … Read more

L.A. Care and Blue Shield Promise Bring Much Needed Community Resource Center to North Long Beach, Enriching the Community with Free Health-Focused Programs and Services USA – English USA – English USA – español Italia – Italiano

by

LONG BEACH, Calif., June 9, 2023 /PRNewswire/ — L.A. Care Health Plan and Blue Shield of California Promise Health Plan today announce the official grand opening celebration for their Community Resource Center in Long Beach. The Center, located at 5599 Atlantic Avenue, is one of 12 out of 14 planned centers jointly operated by the health … Read more

Headline, Upfront, Milestone and Royalty Data for 1,000+ Deals

by

DUBLIN, June 9, 2023 /PRNewswire/ — The “Global Respiratory Partnering 2010-2023: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. Global Respiratory Partnering 2010 to 2023 provides the full collection of over 1,000 Respiratory disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Most of the deals included within … Read more

Skupina Menarini oznamuje na kongresu Evropské hematologické asociace údaje o podskupině NEXPOVIO® (selinexor) ze studie BOSTON a podtrhuje klinický potenciál u relapsu mnohočetného myelomu nereagujícího na jinou léčbu USA – čeština USA – English USA – English USA – español USA – Pусский USA – Deutsch USA – Polski USA – Français

by

Údaje prokazují významné 71% snížení rizika progrese onemocnění nebo úmrtí ve větvi selinexor + bortezomib + dexametazon (SVd). oproti větvi bortezomib + dexametazon (Vd) u pacientů dosud nevystavených inhibitoru proteazomu  Data ukazují významné 47% snížení rizika úmrtí při použití SVd oproti Vd u pacientů s mnohočetným myelomem, kteří nereagují na léčbu lenalidomidem  FLORENCIE, Itálie, 9. … Read more

MOLLI Surgical Honoured as a Top Workplace in Health Care for 2023

by

MOLLI Surgical selected as one of the Best Workplaces in Health Care for second consecutive year TORONTO, June 9, 2023 /PRNewswire/ — MOLLI Surgical is proud to announce that our organization has been recognized on the 2023 Best Workplaces™ in Health Care list. The company received this honour after a thorough and independent analysis conducted by … Read more

Analysis of How and Why companies Enter Companion Diagnostics Partnering Deals

by

DUBLIN, June 9, 2023 /PRNewswire/ — The “Global Companion Diagnostics Partnering Terms and Agreements 2010-2023” report has been added to ResearchAndMarkets.com’s offering. The Global Companion Diagnostics Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 550 companion diagnostics deals and agreements entered into by the worlds leading healthcare … Read more

Menarini Group podczas kongresu Europejskiego Stowarzyszenia Hematologii prezentuje dane podgrupy pacjentów przyjmujących NEXPOVIO® (selineksor) w ramach badania klinicznego BOSTON, zwracając uwagę na potencjał kliniczny preparatu w leczeniu nawracającego/opornego szpiczaka mnogiego USA – Deutsch USA – Deutsch USA – English USA – Français

by

Dane wskazują na znaczące – o 71% – obniżenie ryzyka postępu choroby lub zgonu w grupie przyjmującej selineksor + bortezomib + deksametazon (SVd) w porównaniu do grupy przyjmującej bortezomib + deksametazon (Vd) u pacjentów nieleczonych wcześniej inhibitorami proteasomów. Dane wskazują na znaczące – o 47% obniżenie ryzyka zgonu przy kombinacji SVd w porównaniu do Vd … Read more

MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients

by

JERSEY CITY, N.J., June 9, 2023 /PRNewswire/ — MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy of palbociclib maintenance in combination with second-line endocrine therapy in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer who had showed a confirmed progressive disease on first-linepalbociclib plus … Read more

Mark Runyon of Tampa General Hospital Named a ‘Hospital and Health System CFO to Know’ for 2023

by

The academic health system’s EVP and Chief Financial Officer is recognized by Becker’s Hospital Review for his role in driving Tampa General’s financial performance and operational efficiency while prioritizing patient care. TAMPA, Fla., June 9, 2023 /PRNewswire/ — Mark Runyon, executive vice president and chief financial officer (CFO) of Tampa General Hospital, has been named a … Read more

Ascend Vision Partners and Advanced Eyecare Associates Form Strategic Partnership

by

ORLANDO, Fla., June 9, 2023 /PRNewswire/ — Ascend Vision Partners (“AVP”), a leading administrative service provider for eye care practices, and Advanced Eyecare Associates, a prominent ophthalmic practice in Central Florida, are delighted to announce a strategic partnership aimed at enhancing eye health services across the state. The partnership between AVP and Advanced Eyecare Associates combines … Read more